GET DAILY SIGNALSCorVel (CRVL) Delivers +11% Revenue Growth and +24% EPS Rise in Fiscal Q2
Key Takeaways
- CorVel reported second quarter fiscal 2027 revenue of $267 million, up 11% from $240 million in the same quarter a year earlier.
- Diluted earnings per share rose 24% to $0.67, compared with $0.54 in the prior-year period.
- Gross profit increased 24% to $72.3 million, lifting gross margin to 27% from roughly 24% a year ago.
- The company exited the quarter with $270 million in cash and cash equivalents and no borrowings, while repurchasing $18.1 million of common stock.
- Six-month revenue reached $527 million and diluted EPS reached $1.31, versus $474 million and $1.06 in the prior-year period.
Earnings Context and Why It Matters
CorVel Corporation is a technology-driven provider of workers' compensation, auto, and health insurance services, spanning claims management, clinical care, pharmacy benefits, and payment integrity through its CERIS platform. Its second quarter fiscal 2027 results offer investors a read on demand for its managed-care and network solutions across an evolving healthcare-cost landscape. The quarter stands out for sustained double-digit revenue growth paired with meaningful gross-margin expansion, which points to improved operating leverage. With a debt-free balance sheet and an active buyback program, the results also highlight management's confidence in long-term cash generation while the company continues investing in automation and artificial intelligence across its claims and clinical workflows. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the quarter ended September 30, 2026, CRVL reported revenue of $267 million, an 11% increase from $240 million in the September 2025 quarter. Diluted earnings per share came in at $0.67, up 24% from $0.54 a year earlier, while net income rose to $34.1 million from $27.9 million.
Profitability improved sharply: gross profit climbed 24% to $72.3 million, expanding gross margin to 27% from roughly 24.3% in the prior-year quarter. Income from operations increased 28% to $45.8 million. For the first six months of fiscal 2027, revenue reached $527 million (up from $474 million) and diluted EPS reached $1.31 (up from $1.06). The company ended the quarter with $270 million in cash and cash equivalents, no borrowings, and repurchased $18.1 million of stock during the period. From what I see, these figures reflect steady execution.
Market Reaction and Investor Sentiment
CRVL's fiscal second quarter results were released before the market open on November 3, 2026, with shares trading modestly lower in early activity despite the headline beats on both the top and bottom lines. The relatively muted reaction reflects a market that had already priced in CRVL's consistent pattern of double-digit revenue growth and steady margin improvement. Investors appeared focused on the sustainability of gross-margin gains and whether momentum in the company's Network Solutions and CERIS payment-integrity businesses can persist through the second half of the fiscal year. The continued share repurchases and debt-free balance sheet were viewed favorably as signals of management's long-term confidence.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors should watch whether CRVL can sustain its expanded gross margin as it continues investing in technology and clinical staffing. The company has been broadening its CERIS payment-integrity offerings, including hospital bill audit and professional claims solutions, which management frames as a response to rising medical-cost pressures across workers' compensation and health plans. Successful implementation and scaling of recently signed payer engagements will be a key indicator of future revenue growth.
Another area of focus is the pace of artificial intelligence and automation adoption across CRVL's claims and clinical workflows. While these tools are intended to improve consistency and productivity, the market will monitor whether they translate into sustained operating leverage rather than one-time efficiency gains.
Finally, the company's capital-allocation strategy bears watching. With $270 million in cash, no borrowings, and an active buyback program, CRVL retains flexibility for additional repurchases, product investment, or potential acquisitions. Any commentary on new business wins, claims-volume trends, and medical-cost inflation will help shape expectations for the remainder of fiscal 2027. I’m watching this closely.
Using Tickeron Tools for Deeper Analysis
In my view, Tickeron’s AI Screener provides a practical way to filter stocks by technical patterns, fundamentals, and AI-driven signals. It helps surface ideas and refine watchlists more efficiently than manual methods, which I find useful when reviewing earnings-driven names like CRVL.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CRVL in +1.26% Uptrend, advancing for three consecutive days on November 02, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CRVL advanced for three days, in 227 of 321 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Aroon Indicator entered an Uptrend today. In 182 of 273 cases where CRVL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.
Bearish Trend Analysis
The 10-day RSI Indicator for CRVL moved out of overbought territory on October 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 22 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 58 cases where CRVL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 72%.
The Moving Average Convergence Divergence Histogram (MACD) for CRVL turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 34 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRVL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 58%.
CRVL broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. CRVL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 51 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 78 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRVL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock better than average.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CRVL's P/B Ratio (10.210) is slightly higher than the industry average of (2.673). P/E Ratio (36.729) is within average values for comparable stocks, (18.899). Projected Growth (PEG Ratio) (1.390) is also within normal values, averaging (8.322). Dividend Yield (0.000) settles around the average of (0.042) among similar stocks. P/S Ratio (3.724) is also within normal values, averaging (2.968).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of risk management solutions to employers, third party administrators, insurance companies and government agencies
Industry InsuranceBrokersServices
Advertisement